Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kidney Structure01:45

Kidney Structure

75.2K
The kidneys are two large bean-shaped organs located in the upper abdomen. They filter the blood several times a day to remove toxins and rebalance water and electrolytes of the circulatory system via the renal veins. The kidneys receive blood directly from the heart via the renal arteries. These arteries enter the kidney at the hilum, the concave surface of the bean, where they branch and divide into smaller vessels and capillaries.
75.2K
What are Viruses?00:50

What are Viruses?

128.1K
Overview
128.1K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System01:21

Hepatic Portal System

5.9K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.9K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

247
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
247
External Anatomy of the Kidney01:21

External Anatomy of the Kidney

3.7K
The kidneys are a pair of bean-shaped organs in the human body that play a critical role in maintaining overall health. They filter out waste products from the blood, regulate blood pressure, maintain electrolyte balance, and stimulate the production of red blood cells.
The kidneys are located in the retroperitoneal space on either side of the vertebral column, protected posteriorly by the 11th and 12th ribs. The right kidney sits slightly lower than the left owing to the presence of the liver...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The kidney in the middle: Kidney Disease: Improving Global Outcomes (KDIGO) guidelines address multiple key components of cardiovascular-kidney-metabolic syndrome.

Kidney international·2026
Same author

Kidney Disease: Improving Global Outcomes Green Dialysis Controversies Conference: A Carbon Footprint and Sustainability Report.

Kidney international reports·2026
Same author

The growing role of interventional oncology in the management of hepatic malignancies in France: A nationwide analysis of intervention trends from the French national hospital discharge database.

Diagnostic and interventional imaging·2026
Same author

[Diagnostic approach for metabolic dysfunction associated steatotic liver disease].

La Revue du praticien·2026
Same author

Targeting B cells in immune-mediated kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Kidney international·2026
Same author

Comparative evaluation of regression and machine-learning models for hepatocellular carcinoma risk stratification across diverse aetiologies.

JHEP reports : innovation in hepatology·2026

Related Experiment Video

Updated: Feb 2, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

Hepatitis C virus and the kidney.

Stanislas Pol1, Lucia Parlati2, Michel Jadoul3

  • 1Université Paris Descartes; Hepatology Department, Cochin Hospital, APHP; INSERM U1223, UMS-20 and Center for Translational Science, Institut Pasteur, Paris, France. stanislas.pol@aphp.fr.

Nature Reviews. Nephrology
|November 21, 2018
PubMed
Summary
This summary is machine-generated.

Treating Hepatitis C virus (HCV) infection in patients with chronic kidney disease (CKD) using direct-acting antivirals (DAAs) can achieve sustained virologic response (SVR). This highlights the importance of HCV treatment for improved outcomes in dialysis and transplant patients.

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.0K

Related Experiment Videos

Last Updated: Feb 2, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.0K

Area of Science:

  • Nephrology
  • Hepatology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) infection poses greater risks for dialysis patients and kidney transplant recipients, increasing mortality and complications like allograft/liver failure, diabetes, and cardiovascular issues.
  • HCV infection exacerbates chronic kidney disease (CKD) progression and systemic complications, underscoring the need for effective treatment strategies.

Purpose of the Study:

  • To evaluate the efficacy and necessity of treating HCV in patients with CKD and kidney transplant recipients.
  • To emphasize the benefits of achieving sustained virologic response (SVR) in mitigating HCV-related complications.

Main Methods:

  • Review of current evidence and international guidelines on direct-acting antiviral (DAA) therapy for HCV in CKD patients.
  • Analysis of SVR rates in late-stage CKD and kidney transplant recipients.
  • Consideration of treatment timing and specific patient prioritization.

Main Results:

  • Sustained virologic response (SVR) is achievable in over 95% of patients with late-stage CKD and kidney transplant recipients.
  • Direct-acting antiviral (DAA) treatment is recommended for all CKD patients with HCV, particularly those with symptomatic cryoglobulinemic vasculitis, advanced liver fibrosis, or stage 4-5 CKD.
  • DAA treatment can be safely administered before or after kidney transplantation, with potential benefits for reducing waiting times.

Conclusions:

  • Eliminating HCV in CKD patients is feasible with DAA therapy, leading to attenuated disease complications.
  • Reinforced hygienic measures in dialysis units are crucial to prevent HCV reinfection post-treatment.
  • Ongoing evaluation of the long-term renal safety of DAAs is necessary.